Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 still in force?

Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 is currently in force.

When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 take effect?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 was first recorded in 2024.

How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 have?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 contains 2 sections.

Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024?

The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 is published at lom.agc.gov.my.

/akn/my/act/pua/2024/125

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024

The full official text, structured for quick navigation. Copy any provision or jump straight to a section.

Open source PDF

Type: P.U. (A)
Status: In force
Enacted: 2024
Sections: 2

Quick answer

About this p.u. (a)

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 is Malaysia P.U. (A), cited as P.U. (A) 125 2024, currently marked in force and first recorded in 2024.

Opening note

Preamble

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama

Seksyen 1

Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) 2024.

Seksyen 2

Pindaan Jadual Pertama

(a)

dalam Senarai Racun—

(i)

dengan menggantikan butiran “Adenosine” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 3

Names

Bahagian I

Part I

Bahagian II

Part II

Exempt

Group A

Group B

Group C

Group D

“Adenosine

Medicinal preparations unless exempted

All preparations unless in Group C or exempted

(1)

Raw cordyceps

(2)

Product which is registered under the

Control of Drugs and

Cosmetics

Regulations 1984

containing adenosine from natural resources

(3)

Cosmetic which is notified under the

Control of Drugs and

Cosmetics

Regulations 1984

(4)

Food

P.U. (A) 125 4

(5)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(ii)

dalam senarai “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”—

dengan menggantikan butiran “Ephedra, alkaloids of, including synthetic preparations” dengan butiran

“Ephedra, alkaloids of”;

dengan menggantikan butiran “Rauwolfia, alkaloids of, including synthetic preparations” dengan butiran

“Rauwolfia, alkaloids of”; dan dengan menggantikan butiran “Vinca, alkaloids of; including synthetic preparations” dengan butiran

"Vinca, alkaloids of”;

P.U. (A) 125 5

(iii)

dengan menggantikan butiran “Azelaic Acid” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Azelaic acid

All medicinal preparations unless in Group C

Medicinal preparations for external use

All preparations unless in Group B or Group C

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(iv)

dengan menggantikan butiran “Boric acid and Sodium borate” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 6

Names

Exempt

Group A

Group B

Group C

Group D

“Boric acid and Sodium borate

All medicinal preparations unless exempted

Preparations other than medicinal preparations unless exempted

(1)

Preparations containing not more than 5% of

Boric acid, or 5%

of Sodium borate, or 5%

of a combination of

Boric acid and

Sodium borate

(2)

Preparations ready for use as pesticides or fertilizers

(3)

Its analogues, homologues, compounds, intermediates,

P.U. (A) 125 7

(v)

dengan menggantikan butiran “Botulinum toxin; natural or synthetic” dengan butiran “Botulinum toxin”;

(vi)

dengan menggantikan butiran “Chloroform” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Chloroform

Veterinary preparations for food-producing animals

Medicinal preparation unless in Group A or exempted

All preparation unless in

Group A,

Group C or exempted

(1)

Strengths under 10%

unless in

Group A

(2)

Its analogues, homologues, compounds, derivatives, esters, ethers, salts and other substances structurally derived”;

P.U. (A) 125 8

intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(vii)

dengan menggantikan butiran “Corticotrophins, natural and synthetic” dengan butiran “Corticotrophins”;

(viii)

dengan menggantikan butiran “Ethylidene diacetate” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ethylidene diacetate

All preparations unless exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other

P.U. (A) 125 9

substances structurally derived”;

(ix)

dengan menggantikan butiran “Gamma Butyrolactone” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Gamma

Butyrolactone

All preparations unless exempted

(1)

When used as food additive in food

(2)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(x)

dengan menggantikan butiran “Hypothalamic Hormones and their synthetic analogues” dengan butiran

“Hypothalamic Hormones and their analogues”;

P.U. (A) 125 10

(xi)

dengan menggantikan butiran “Iodine” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Iodine

All preparations for parenteral administration.

All medicinal preparations containing 2%

and above of iodine

All preparations unless in

Group C or exempted

(1)

Preparations containing less than 2% of iodine unless in

Group C

(2)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xii)

dengan menggantikan butiran “Local anaesthetics; the following: their salts; their homologues and analogues;

their molecular compounds:” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 11

Names

Exempt

Group A

Group B

Group C

Group D

“Local anaesthetics;

the following:

their salts;

their homologues and analogues;

their molecular compounds:

All preparations containing local anaesthetics unless in

Group B,

Group C or

Group D

All preparations in pharmaceutical dosage forms unless in Group C

(1)

All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use

(2)

Suppositories, lozenges and pastilles

(3)

Preparations in the form of cartridges for dental use containing 2% or

Preparations for laboratory use

Denatonium benzoate”;

P.U. (A) 125 12

less of local anaesthetic

(xiii)

dengan memasukkan selepas butiran “Methyprylone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Methylthioninium chloride

All preparations for parenteral administration

All preparations unless in Group B”;

(xiv)

dalam senarai “Monoclonal antibody; includes the following:”—

dengan memasukkan selepas butiran “Alirocumab” butiran “Amivantamab”;

dengan memasukkan selepas butiran “Cetuximab” butiran “Cilgavimab”; dan dengan memasukkan selepas butiran “Sotrovimab” butiran “Tixagevimab”;

(xv)

dengan menggantikan butiran “Nitrobenzene” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 13

Names

Exempt

Group A

Group B

Group C

Group D

“Nitrobenzene

All preparations containing 0.1% and over unless exempted

(1)

Under 0.1%

(2)

Under 1% in soap

(3)

Under 5% in polishes

(4)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xvi)

dengan menggantikan butiran “Nitrophenols, ortho, meta and para” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 14

Names

Exempt

Group A

Group B

Group C

Group D

“Nitrophenols, ortho, meta and para

All preparations unless exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xvii)

dengan menggantikan butiran “Oxalic acid; metallic oxalates” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Oxalic acid;

metallic oxalates

All preparations unless exempted

(1)

Laundry blue, polishes, cleaning powders or scouring products, containing the equivalent of not more than 10% of oxalic acid dihydrate

P.U. (A) 125 15

(2)

Ink eradicators containing not more than 5% of oxalic acid

(3)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xviii)

dengan menggantikan butiran “Oxytocins; natural and synthetic” dengan butiran “Oxytocins”;

(xix)

dengan menggantikan butiran “Phenolphthalein” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 16

Names

Exempt

Group A

Group B

Group C

Group D

“Phenolphthalein

All preparations for therapeutic use

All preparations unless in

Group C or exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xx)

dengan menggantikan butiran “Picric acid” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Picric acid

All preparations unless exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxi)

dengan menggantikan butiran “Piperazine unless stated elsewhere in the List” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

P.U. (A) 125 17

Names

Exempt

Group A

Group B

Group C

Group D

“Piperazine unless stated elsewhere in the List

All preparations unless exempted

(1)

Cosmetic which is notified under the Control of Drugs and

Cosmetics

Regulations 1984

(2)

Product which is registered under the

Control of

Drugs and

Cosmetics

Regulations 1984

(3)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other

P.U. (A) 125 18

substances structurally derived”;

(xxii)

dengan menggantikan butiran “Prostaglandins and its synthetic derivatives; their salts; their esters”

dengan butiran “Prostaglandins and its derivatives; their salts; their esters”;

(xxiii)

dengan memasukkan selepas butiran “Regorafenib” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Remdesivir

All preparations”;

(xxiv)

dengan memasukkan selepas butiran “Selexipag” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

P.U. (A) 125 19

Names

Exempt

Group A

Group B

Group C

Group D

“Selumetinib

All preparations”;

(xxv)

dengan menggantikan butiran “Sex hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:” dengan butiran “Sex Hormones-androgenic, oestrogenic and progestational, the following:”;

(xxvi)

dengan menggantikan butiran “Vasopressins, natural and synthetic” dengan butiran “Vasopressins”; dan

(xxvii)

dengan memasukkan selepas butiran “Zoxazolamine; its salts” dan butir-butir yang berhubungan dengannya perenggan yang berikut:

“In the construction of this List, unless the contrary intention appears, a reference to a substance mentioned in the first column of this Schedule shall include a reference to that substance prepared either from natural sources or synthetically.”; dan

(b)

dalam Lampiran kepada Senarai Racun—

(i)

dalam senarai “Antihypertensives:”, dengan menggantikan butiran “Rauwolfia, alkaloids of, including synthetic preparations” dengan butiran “Rauwolfia, alkaloids of”;

P.U. (A) 125 20

(ii)

dalam senarai “Antineoplastic agents and Immunosuppressants:”—

dengan memasukkan selepas butiran “Aminoglutethimide” butiran “Amivantamab”;

dengan memasukkan selepas butiran “Secukinumab” butiran “Selumetinib”; dan dengan menggantikan butiran “Vinca, alkaloids of, including synthetic preparations” dengan butiran

“Vinca, alkaloids of”;

(iii)

dalam senarai “Antiviral agents:”—

dengan memasukkan selepas butiran “Boceprevir” butiran “Cilgavimab”;

dengan memasukkan selepas butiran “Regdanvimab” butiran “Remdesivir”; dan dengan memasukkan selepas butiran “Tenofovir” butiran “Tixagevimab”;

(iv)

dalam senarai “Hormones:”—

dengan menggantikan butiran “Corticotrophins, natural and synthetic” dengan butiran “Corticotrophins”;

P.U. (A) 125 21

dengan menggantikan butiran “Hypothalamic Hormones and their synthetic analogues” dengan butiran

“Hypothalamic Hormones and their analogues”;

dengan menggantikan butiran “Oxytocins, natural and synthetic” dengan butiran “Oxytocins”;

(D)

dengan menggantikan butiran

“Sex

Hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:” dengan butiran “Sex Hormones-androgenic, oestrogenic and progestational, the following:”; dan

(E)

dengan menggantikan butiran “Vasopressins, natural and synthetic” dengan butiran “Vasopressins”;

(v)

dalam senarai “Sympathomimetic amines:”, dengan menggantikan butiran “Ephedra, alkaloids of, including synthetic preparations” dengan butiran “Ephedra, alkaloids of”; dan

(vi)

dalam senarai “Miscellaneous:”—

dengan menggantikan butiran “Botulinum toxin; natural or synthetic” dengan butiran “Botulinum toxin”;

dengan memasukkan selepas butiran “Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-

dimethylbutanoate (5F-MDMB-PICA)” butiran “Methylthioninium chloride”; dan

P.U. (A) 125 22

dengan menggantikan butiran “Prostaglandins and its synthetic derivatives; their salts; their esters” dengan butiran “Prostaglandins and its derivatives; their salts; their esters”.

Dibuat 25 April 2024

[KKM.600-18/2/95; PN(PU2)172/JLD.20]

DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD

Menteri Kesihatan

P.U. (A) 125 23

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2024

Opening note

Preamble

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) Order 2024. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule—

(a)

in the Poisons List—

(i)

by substituting for the item “Adenosine” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Adenosine

Medicinal preparations unless exempted

All preparations unless in Group C or exempted

(1)

Raw cordyceps

(2)

Product which is

P.U. (A) 125 24

registered under the

Control of Drugs and

Cosmetics

Regulations 1984

containing adenosine from natural resources

(3)

Cosmetic which is notified under the

Control of Drugs and

Cosmetics

Regulations 1984

(4)

Food

(5)

Its analogues, homologues, compounds, intermediates, derivatives, esters,

P.U. (A) 125 25

ethers, salts and other substances structurally derived”;

(ii)

in the list of “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”—

by substituting for the item “Ephedra, alkaloids of, including synthetic preparations” the item

“Ephedra, alkaloids of”;

by substituting for the item “Rauwolfia, alkaloids of, including synthetic preparations” the item

“Rauwolfia, alkaloids of”; and by substituting for the item “Vinca, alkaloids of; including synthetic preparations” the item

“Vinca, alkaloids of”;

(iii)

by substituting for the item “Azelaic Acid” and the particulars relating to it the following item and particulars:

P.U. (A) 125 26

Names

Exempt

Group A

Group B

Group C

Group D

“Azelaic acid

All medicinal preparations unless in Group C

Medicinal preparations for external use

All preparations unless in Group

B or Group C

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(iv)

by substituting for the item “Boric acid and Sodium borate” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Boric acid and Sodium borate

All medicinal preparations unless exempted

Preparations other than medicinal preparations

(1)

Preparations containing not more than 5% of

Boric acid, or 5%

P.U. (A) 125 27

unless exempted of Sodium borate, or 5%

of a combination of

Boric acid and

Sodium borate

(2)

Preparations ready for use as pesticides or fertilizers

(3)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

P.U. (A) 125 28

(v)

by substituting for the item “Botulinum toxin; natural or synthetic” the item “Botulinum toxin”;

(vi)

by substituting for the item “Chloroform” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Chloroform

Veterinary preparations for food-producing animals

Medicinal preparation unless in Group A or exempted

All preparation unless in

Group A,

Group C or exempted

(1)

Strengths under 10%

unless in

Group A

(2)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(vii)

by substituting for the item “Corticotrophins natural and synthetic” the item “Corticotrophins”;

P.U. (A) 125 29

(viii)

by substituting for the item “Ethylidene diacetate” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Ethylidene diacetate

All preparations unless exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(ix)

by substituting for the item “Gamma Butyrolactone” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Gamma

Butyrolactone

All preparations unless exempted

(1)

When used as food additive in food

P.U. (A) 125 30

(2)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(x)

by substituting for the item “Hypothalamic Hormones and their synthetic analogues” the item “Hypothalamic

Hormones and their analogues”;

(xi)

by substituting for the item “Iodine” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Iodine

All preparations for parenteral administration.

All preparations unless in

Group C or exempted

(1)

Preparations containing less than 2% of iodine unless in

Group C

P.U. (A) 125 31

All medicinal preparations containing 2%

and above of iodine

(2)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xii)

by substituting for the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Local anaesthetics;

the following:

their salts;

their homologues and

All preparations containing local anaesthetics unless in

Group B,

All preparations in pharmaceutical dosage forms unless in Group C

(1)

All preparations in pharmaceutical dosage form for topical use in the nose, eyes and

Preparations for laboratory use

Denatonium benzoate”;

P.U. (A) 125 32

analogues;

their molecular compounds:

Group C or

Group D ears or external use

(2)

Suppositories, lozenges and pastilles

(3)

Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic

(xiii)

by inserting after the item “Methyprylone” and the particulars relating to it the following item and particulars:

P.U. (A) 125 33

Names

Exempt

Group A

Group B

Group C

Group D

“Methylthioninium chloride

All preparations for parenteral administration

All preparations unless in Group B”;

(xiv)

in the list of “Monoclonal antibody; includes the following:”—

by inserting after the item “Alirocumab” the item “Amivantamab”;

by inserting after the item “Cetuximab” the item “Cilgavimab”; and by inserting after the item “Sotrovimab” the item “Tixagevimab”;

(xv)

by substituting for the item “Nitrobenzene” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Nitrobenzene

All preparations containing

(1)

Under 0.1%

(2)

Under 1% in soap

P.U. (A) 125 34 0.1% and over unless exempted

(3)

Under 5% in polishes

(4)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xvi)

by substituting for the item “Nitrophenols, ortho, meta and para” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Nitrophenols, ortho, meta and para

All preparations unless exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

P.U. (A) 125 35

(xvii)

by substituting for the item “Oxalic acid; metallic oxalates” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Oxalic acid;

metallic oxalates

All preparations unless exempted

(1)

Laundry blue, polishes, cleaning powders or scouring products, containing the equivalent of not more than 10% of oxalic acid dehydrate

(2)

Ink eradicators containing not more than 5% of oxalic acid

(3)

Its analogues, homologues, compounds, intermediates,

P.U. (A) 125 36

derivatives, esters, ethers, salts and other substances structurally derived”;

(xviii)

by substituting for the item “Oxytocins; natural and synthetic” the item “Oxytocins”;

(xix)

by substituting for the item “Phenolphthalein” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Phenolphthalein

All preparations for therapeutic use

All preparations unless in

Group C or exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xx)

by substituting for the item “Picric acid” and the particulars relating to it the following item and particulars:

P.U. (A) 125 37

Names

Exempt

Group A

Group B

Group C

Group D

“Picric acid

All preparations unless exempted

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxi)

by substituting for the item “Piperazine unless stated elsewhere in the List” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Piperazine unless stated elsewhere in the List

All preparations unless exempted

(1)

Cosmetic which is notified under the

Control of

Drugs and

Cosmetics

Regulations 1984

P.U. (A) 125 38

(2)

Product which is registered under the

Control of

Drugs and

Cosmetics

Regulations 1984

(3)

Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxii)

by substituting for the item “Prostaglandins and its synthetic derivatives; their salts; their esters” the item

“Prostaglandins and its derivatives; their salts; their esters”;

(xxiii)

by inserting after the item “Regorafenib” and the particulars relating to it the following item and particulars:

P.U. (A) 125 39

Names

Exempt

Group A

Group B

Group C

Group D

“Remdesivir

All preparations”;

(xxiv)

by inserting after the item “Selexipag” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Selumetinib

All preparations”;

(xxv)

by substituting for the item “Sex hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:” the item “Sex Hormones-androgenic, oestrogenic and progestational, the following:”;

(xxvi)

by substituting for the item “Vasopressins, natural and synthetic” the item “Vasopressins”; and

(xxvii)

by inserting after the item “Zoxazolamine; its salts” and the particulars relating to it the following paragraph:

P.U. (A) 125 40

(b)

in the Appendix to the Poisons List—

(i)

in the list of “Antihypertensives:”, by substituting for the item “Rauwolfia, alkaloids of, including synthetic preparations” the item “Rauwolfia, alkaloids of”;

(ii)

in the list of “Antineoplastic agents and Immunosuppressants:”—

by inserting after the item “Aminoglutethimide” the item “Amivantamab”;

by inserting after the item “Secukinumab” the item “Selumetinib”; and by substituting for the item “Vinca, alkaloids of, including synthetic preparations” the item “Vinca,

Alkaloids of”;

(iii)

in the list of “Antiviral agents:”—

by inserting after the item “Boceprevir” the item “Cilgavimab”;

by inserting after the item “Regdanvimab” the item “Remdesivir”; and by inserting after the item “Tenofovir” the item “Tixagevimab”;

P.U. (A) 125 41

(iv)

in the list of “Hormones:”—

by substituting for the item “Corticotrophins natural and synthetic” the item “Corticotrophins”;

by substituting for the item “Hypothalamic Hormones and their synthetic analogues” the item “Hypothalamic

Hormones and their analogues”;

by substituting for the item “Oxytocins; natural and synthetic” the item “Oxytocins”;

(D)

by substituting for the item “Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:” the item “Sex Hormones-androgenic, oestrogenic and progestational, the following:”; and

(E)

by substituting for the item “Vasopressins, natural and synthetic” the item “Vasopressins”;

(v)

in the list of “Sympathomimetic amines:”, by substituting for the item “Ephedra, alkaloids of, including synthetic preparations” the item “Ephedra, alkaloids of”; and

(vi)

in the list of “Miscellaneous:”—

by substituting for the item “Botulinum toxin; natural or synthetic” the item “Botulinum toxin”;

P.U. (A) 125 42

by inserting after the item “Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-

dimethylbutanoate (5F-MDMB-PICA)” the item “Methylthioninium chloride”; and by substituting for the item “Prostaglandins and its synthetic derivatives; their salts; their esters” the item

“Prostaglandins and its derivatives; their salts; their esters”.

Made 25 April 2024

[KKM.600-18/2/95; PN(PU2)172/JLD.20]

DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD

Minister of Health

Common questions

What is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 is Malaysia P.U. (A), cited as P.U. (A) 125 2024, currently marked in force and first recorded in 2024.
Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 still in force?: Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 is currently in force.
When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 take effect?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 was first recorded in 2024.
How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 have?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 contains 2 sections.
Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024?: The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024 is published at lom.agc.gov.my.